Last reviewed · How we verify
CSL412
CSL412 is a vaccine.
CSL412 is a vaccine. Used for Influenza prevention.
At a glance
| Generic name | CSL412 |
|---|---|
| Sponsor | Seqirus |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
CSL412 is a vaccine that works by stimulating the body's immune system to produce a specific response against the target pathogen.
Approved indications
- Influenza prevention
Common side effects
- Injection site pain
Key clinical trials
- A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL412 CI brief — competitive landscape report
- CSL412 updates RSS · CI watch RSS
- Seqirus portfolio CI